Bioasis Technologies Inc
BTI.CA
$0.00
Closing
0.00
1D
0.00
YTD
Market cap
$290660
52 week high
$0.01
52 week low
$0.00
Volume
814
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$290660
Analysts' Rating
-
Price Target (Mean)
-
Total Analysts
1
P/E
Operating Margin
-469.22%
Beta
0.46
Revenue Growth (Annual)
-
52 week high
$0.01
52 week low
$0.00
Div. Yield
%
EPS Annual Growth
-27.52
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Bioasis Technologies Inc. is a Canada-based development stage biopharmaceutical company engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The Company is engaged in the development of the xB3 platform, a technology for the delivery of therapeutics across the blood brain barrier (BBB) and the treatment of central nervous system (CNS) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. xB3 is based on a human transport protein found circulating at low levels in the blood. The xB3 platform has an efficacy in its ability to shuttle molecules across the blood-brain barrier and reach its targets within the brain through a process called receptor-mediated transcytosis. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.
